Q-omics provides the consensus-scored MIR3116-1 profile across patient tissues and cancer cell-line models. MIR3116-1 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, MIR3116-1 is differentially expressed in 2, with the highest sampling consensus in PRAD. Additionally, MIR3116-1 RNA expression shows 6,111 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight READ, PRAD, and STAD as cancer lineages where MIR3116-1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR3116-1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR3116-1 survival associations across molecular data types. MIR3116-1 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR3116-1 RNA expression–survival associations across cancer types. High MIR3116-1 expression shows unfavorable associations in READ, TGCT, ACC, HNSC and SARC, but favorable associations in BRCA. The READ Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for MIR3116-1 RNA expression.
This table summarizes MIR3116-1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in PRAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR3116-1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR3116-1 shows lower tumor expression in KICH and higher tumor expression in PRAD. The PRAD box plot shows higher MIR3116-1 RNA expression in tumor versus normal tissue (log2 FC = +0.203, t-test p = .037).
This table shows molecular features associated with MIR3116-1 in patient tissues and cancer cell lines. In patient samples, MIR3116-1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
